Cell Wall Synthesis Inhibitors: Beta-Lactams and Penicillins

Common Problem Bacteria in Antibiotic Therapy

  • Staphylococcus aureus: Gram-positive pathogen naturally susceptible to β\beta-lactams, but commonly produces penicillinase. Methicillin-resistant S. aureus (MRSA) possesses altered penicillin-binding proteins (PBPs), conferring resistance to nearly all β\beta-lactams.

  • Streptococci: Gram-positive pathogens that largely remain susceptible to penicillin, with the major exception of Streptococcus pneumoniae, which frequently displays resistance.

  • Enterococci: Relatives of streptococci displaying elevated baseline resistance, occasionally extending to glycopeptides.

  • Enteric Bacteria: Gram-negative rods (e.g., Escherichia coli, Klebsiella pneumoniae) with high clinical relevance; K. pneumoniae is particularly prone to acquiring multidrug resistance.

  • Non-Fermenting Rods: Aerobic Gram-negative opportunistic pathogens (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia) exhibiting broad-spectrum resistance due to restricted outer membrane permeability.

Bacterial Cell Wall Architecture and Synthesis


Bacterial cell wall architecture in Gram-positive and Gram-negative bacteria

  • Gram-Positive Cell Wall:

    • Thick peptidoglycan layer containing teichoic acid and lipoteichoic acid.

    • Surrounded by an optional capsule; lacks an outer membrane.

  • Gram-Negative Cell Wall:

    • Thin peptidoglycan layer situated within the periplasmic space.

    • Enclosed by an outer membrane containing lipopolysaccharide (LPS) and porin channels.

  • Peptidoglycan Composition:

    • Repeating disaccharide backbone: N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM).

    • Cross-linked via oligopeptide bridges attached to NAM.

    • Gram-positive cross-link: Typically contains L-Ala, D-Glut, L-Lys, D-Ala, and a pentaglycine bridge (Gly5\text{Gly}_5).

    • Gram-negative cross-link: Contains diaminopimelic acid (DAP) directly cross-linking peptide side chains.

Targets of Cell Wall Synthesis Inhibitors


Sites of action of cell wall synthesis inhibitors

  • Cytoplasmic Steps:

    • Fosfomycin: Blocks the initial condensation of phosphoenolpyruvate with NAG to form NAM.

    • Cycloserine: Inhibits the synthesis of the terminal D-Ala-D-Ala dipeptide.

  • Membrane Transport:

    • Bacitracin: Inhibits lipid carrier (bactoprenol pyrophosphate) dephosphorylation, halting the translocation of peptidoglycan subunits across the cell membrane.

  • Cell Wall Assembly:

    • Glycopeptides: Bind directly to terminal D-Ala-D-Ala residues, sterically hindering transglycosylation and transpeptidation.

    • β\beta-Lactams: Inhibit transpeptidases (Penicillin-Binding Proteins, PBPs) responsible for cross-linking peptidoglycan glycan strands.

The β\beta-Lactam Antibiotics


Core four-membered ring structure of beta-lactams

  • Structure and Mechanism:

    • Characterized by a core four-membered β\beta-lactam ring.

    • Covalently block transpeptidases by forming an acyl-enzyme intermediate with active-site serine residues (PBP–Ser-OH).

    • Different β\beta-lactams exhibit distinct binding affinities for specific PBPs.

  • Four Major Structural Classes:

    • Penicillins

    • Cephalosporins

    • Carbapenems

    • Monobactams

Mechanisms of β\beta-Lactam Resistance

  • Target Modification (PBPs):

    • Acquired low-affinity PBPs prevent drug binding.

    • Transferred via horizontal gene transfer (e.g., PBP2 replaced by PBP2a in MRSA) or accumulated via mutations/recombinations (e.g., Streptococcus pneumoniae).

  • Decreased Intracellular Concentration:

    • Limited Uptake: Downregulation or structural loss of outer membrane porins in Gram-negatives.

    • Increased Efflux: Upregulated active multidrug efflux pumps; primary driver of high-level resistance in non-fermenting rods like Pseudomonas.

  • Enzymatic Inactivation (β\beta-Lactamases):

    • Secreted extracellularly by Gram-positive bacteria (e.g., S. aureus penicillinase).

    • Retained in the periplasmic space by Gram-negative bacteria.

    • Divided into 4 functional classes:

    • Class A: Serine β\beta-lactamases (penicillinases, ESBLs, carbapenemases).

    • Class B: Metallo-β\beta-lactamases (MBLs); depend on divalent cations (Zn2+\text{Zn}^{2+}), inhibited by EDTA, resistant to traditional inhibitors, hydrolyze carbapenems.

    • Class C: AmpC cephalosporinases (serine active site).

    • Class D: Oxacillinases / OXA carbapenemases (serine active site).

β\beta-Lactamase Inhibitors

  • Traditional (β\beta-Lactam Structure):

    • Clavulanic acid, sulbactam, tazobactam.

    • Inhibit Class A penicillinases and ESBLs; ineffective against Class B MBLs and Class C AmpC.

    • Sulbactam possesses intrinsic direct antibacterial activity against Acinetobacter baumannii.

  • New Non-β\beta-Lactam Inhibitors:

    • Diazabicyclooctanones (DBO): Avibactam.

    • Boronic Acid Derivatives: Vaborbactam.

    • Extended coverage against Class A carbapenemases, Class C (AmpC), and selected Class D enzymes.

Classes and Clinical Pharmacology of Penicillins

  • Natural Penicillins:

    • Examples: Penicillin G (IV/IM), Penicillin V (oral), Procaine penicillin (depot), Benzathine penicillin (depot IM only).

    • Susceptible to β\beta-lactamase degradation; mainly used for confirmed Streptococcus pyogenes, Treponema pallidum (syphilis), and susceptible Streptococcus pneumoniae or Neisseria meningitidis.

  • Anti-Staphylococcal Penicillins (Penicillinase-Resistant):

    • Examples: Methicillin (historical), nafcillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin.

    • Bulky side chain resists staphylococcal penicillinase; treatment of choice for MSSA (kill faster than vancomycin).

    • Eliminated primarily via hepatic clearance rather than renal mechanisms; inactive against MRSA and Gram-negative bacilli.

  • Aminopenicillins:

    • Examples: Ampicillin (IV/oral), amoxicillin (superior oral bioavailability).

    • Hydrophilic side chains improve passage through Gram-negative porins; active against enterococci, Listeria monocytogenes, and non-producing Gram-negative bacilli.

    • Combined with inhibitors (Ampicillin-sulbactam, Amoxicillin-clavulanic acid) to treat otitis media, sinusitis, animal/human bites, and mixed soft tissue infections.

  • Anti-Pseudomonal Penicillins:

    • Carboxypenicillins: Carbenicillin, ticarcillin.

    • Acyl Ureidopenicillins: Piperacillin, mezlocillin, azlocillin.

    • Cover Pseudomonas aeruginosa and enteric rods; hydrolyzable by β\beta-lactamases unless combined with an inhibitor (e.g., Piperacillin-tazobactam for nosocomial and polymicrobial infections).

  • General Pharmacokinetic Considerations:

    • Short biological half-lives requiring frequent dosing.

    • Low intracellular penetration and limited crossing of intact blood-brain and blood-ocular barriers (entry occurs during active meningeal inflammation).

    • Excreted unchanged in urine via active tubular secretion; clearance is competitively inhibited by probenecid.

Monobactams

  • Aztreonam:

    • Monocyclic β\beta-lactam ring structure.

    • Spectrum: Strictly active against aerobic Gram-negative bacteria (including Pseudomonas aeruginosa); completely inactive against Gram-positive bacteria and anaerobes.

    • Can be safely administered to patients with severe IgE-mediated penicillin allergies.

    • Stable against hydrolysis by metallo-β\beta-lactamases (MBLs).